

- Abegg, M. A., Alabarse, P. V. G., Schüller, Á. K. & Benfato, M. S. 2012. Glutathione levels in and total antioxidant capacity of *Candida* sp. cells exposed to oxidative stress caused by hydrogen peroxide. *Revista da Sociedade Brasileira de Medicina Tropical*, 45, 620-626.
- Abrantes, P. M. D. S., McArthur, C. P. & Africa, C. W. J. 2014. Multi-drug resistant (MDR) oral *Candida* species isolated from HIV-positive patients in South Africa and Cameroon. *Diagnostic Microbiology and Infectious Disease*, 79, 222-227.
- Abrão, P. H. O., Pizi, R. B., De Souza, T. B., Silva, N. C., Fregnan, A. M., Silva, F. N., Coelho, L. F. L., Malaquias, L. C. C., Dias, A. L. T., Dias, D. F., Veloso, M. P. & Carvalho, D. T. 2015. Synthesis and biological evaluation of new eugenol Mannich bases as promising antifungal agents. *Chemical Biology & Drug Design*, 86, 459-465.
- Africa, C. W. J. & Abrantes, P. M. D. S. 2016. *Candida* antifungal drug resistance in sub-Saharan African populations: A systematic review. *F1000Research*, 5, 2832.
- Ahmad, A., Wani, M. Y., Khan, A., Manzoor, N. & Molepo, J. 2015. Synergistic interactions of eugenol-tosylate and its congeners with fluconazole against *Candida albicans*. *PLOS One*, 10, e0145053.
- Ahmad, A., Khan, A., Akhtar, F., Yousuf, S., Xess, I., Khan, L. A. & Manzoor, N. 2011. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against *Candida*. *European Journal of Clinical Microbiology & Infectious Diseases*, 30, 41-50.
- Ahmad, A., Khan, A., Manzoor, N. & Khan, L. A. 2010. Evolution of ergosterol biosynthesis inhibitors as fungicidal against *Candida*. *Microbial Pathogenesis*, 48, 35-41.

- Ahmad, A., Molepo, J. & Patel, M. 2016. Challenges in the development of antifungal agents against *Candida*: Scope of phytochemical research. *Current Pharmaceutical Design*, 22, 4135-4150.
- Ahmad, N., Alam, M. K., Shehbaz, A., Khan, A., Mannan, A., Hakim, S. R., Bisht, D. & Owais, M. 2005. Antimicrobial activity of clove oil and its potential in the treatment of vaginal candidiasis. *Journal of Drug Targeting*, 13, 555-561.
- Akpan, A. & Morgan, R. 2010. Oral candidiasis. *Postgraduate Medical Journal*, 78, 455-459.
- Albrecht, A., Felk, A., Pichova, I., Naglik, J. R., Schaller, M., De Groot, P., Maccallum, D., Odds, F. C., Schäfer, W., Klis, F., Monod, M. & Hube, B. 2006. Glycosylphosphatidylinositol-anchored Proteases of *Candida albicans* target proteins necessary for both cellular processes and host-pathogen interactions. *Journal of Biological Chemistry*, 281, 688-694.
- Almeida, B., Silva, A., Mesquita, A., Sampaio-Marques, B., Rodrigues, F. & Ludovico, P. 2008. Drug-induced apoptosis in yeast. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1783, 1436-1448.
- Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., Uno, B. E., Wildeman, E. L., Gonen, T., Rienstra, C. M. & Burke, M. D. 2014. Amphotericin forms an extramembranous and fungicidal sterol sponge. *Nature Chemical Biology*, 10, 400-406.
- Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Yamamoto, Y., Kuroda, K. & Ueda, M. 2011. Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in *Candida albicans*. *The Journal of Biochemistry*, 150, 431-438.
- Bassetti, M., Taramasso, L., Nicco, E., Molinari, M. P., Mussap, M. & Viscoli, C. 2011. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. *PLOS One*, 6, e24198.

- Berman, J. & Sudbery, P. E. 2002. *Candida albicans*: A molecular revolution built on lessons from budding yeast. *Nature Reviews Genetics*, 3, 918-931.
- Bitew, A. & Abebaw, Y. 2018. Vulvovaginal candidiasis: species distribution of *Candida* and their antifungal susceptibility pattern. *BMC Women's Health*, 18.
- Bondaryk, M., Kurzątkowski, W. & Staniszevska, M. 2013. Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. *Advances in Dermatology and Allergology*, 5, 293-301.
- Bongomin, F., Gago, S., Oladele, R. & Denning, D. 2017. Global and multi-national prevalence of fungal diseases—estimate precision. *Journal of Fungi*, 3, 57.
- Bougnoux, M.-E., Kac, G., Aegerter, P., D'enfert, C. & Fagon, J.-Y. 2008. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. *Intensive Care Medicine*, 34, 292-299.
- Braun, R. J., Zischka, H., Madeo, F., Eisenberg, T., Wissing, S., Büttner, S., Engelhardt, S. M., Büringer, D. & Ueffing, M. 2006. Crucial mitochondrial impairment upon CDC48 mutation in apoptotic Yeast. *Journal of Biological Chemistry*, 281, 25757-25767.
- Brown, G. D., Denning, D. W., Gow, N. a. R., Levitz, S. M., Netea, M. G. & White, T. C. 2012. Hidden killers: Human fungal infections. *Science Translational Medicine*, 4, 165rv13-165rv13.
- Butler, M. S., Robertson, A. a. B. & Cooper, M. A. 2014. Natural product and natural product derived drugs in clinical trials. *Natural Product Reports*, 31, 1612-1661.
- Calandra, T., Roberts, J. A., Antonelli, M., Bassetti, M. & Vincent, J.-L. 2016. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. *Critical Care*, 20.
- Calderone, R. A. 2002. Introduction and historical perspectives. In: Calderone RA, editor. *Candida and Candidiasis*. American Society of Microbiology Press, Washington, DC, pp: 3-13.

- Campoy, S. & Adrio, J. L. 2017. Antifungals. *Biochemical Pharmacology*, 133, 86-96.
- Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A. & Monk, B. C. 2009. Efflux-mediated antifungal drug resistance. *Clinical Microbiology Reviews*, 22, 291-321.
- Carmona-Gutierrez, D., Eisenberg, T., Büttner, S., Meisinger, C., Kroemer, G. & Madeo, F. 2010. Apoptosis in yeast: triggers, pathways, subroutines. *Cell Death & Differentiation*, 17, 763-773.
- Carrasco, H., Raimondi, M., Svetaz, L., Liberto, M. D., Rodriguez, M. V., Espinoza, L., Madrid, A. & Zacchino, S. 2012. Antifungal activity of eugenol analogues. Influence of different substituents and studies on mechanism of action. *Molecules*, 17, 1002-1024.
- Cassone, A., Mason, R. E. & Kerridge, D. 1981. Lysis of growing yeast-form cells of *Candida albicans* by echinocandin: A cytological study. *Medical Mycology*, 19, 97-110.
- Cegelski, L., Marshall, G. R., Eldridge, G. R. & Hultgren, S. J. 2008. The biology and future prospects of antivirulence therapies. *Nature Reviews Microbiology*, 6, 17-27.
- Chaffin, W. L., López-Ribot, J. L., Casanova, M., Gozalbo, D. & Martínez, J. P. 1998. Cell wall and secreted proteins of *Candida albicans*: Identification, function, and expression. *Microbiology and Molecular Biology Reviews*, 62, 130-180.
- Chami, N., Bennis, S., Chami, F., Aboussekhra, A. & Remmal, A. 2005. Study of anticandidal activity of carvacrol and eugenol *in vitro* and *in vivo*. *Oral Microbiology and Immunology*, 20, 106-111.
- Chami, N., Chami, F., Bennis, S., Trouillas, J. & Remmal, A. 2004. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats. *Brazilian Journal of Infectious Diseases*, 8.
- Chang, Y. L., Yu, S. J., Heitman, J., Wellington, M. & Chen, Y. L. 2017. New facets of antifungal therapy. *Virulence*, 8, 222-236.

- Chin, V., Lee, T., Rusliza, B. & Chong, P. 2016. Dissecting *Candida albicans* infection from the perspective of *C. albicans* virulence and omics approaches on host–pathogen interaction: A review. *International Journal of Molecular Sciences*, 17, 1643.
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J. & Chiller, T. M. 2012. Changes in incidence and antifungal drug resistance in candidemia: Results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. *Clinical Infectious Diseases*, 55, 1352-1361.
- Correia, A., Lermann, U., Teixeira, L., Cerca, F., Botelho, S., Gil Da Costa, R. M., Sampaio, P., Gartner, F., Morschhauser, J., Vilanova, M. & Pais, C. 2010. Limited role of secreted aspartyl proteinases Sap1 to Sap6 in *Candida albicans* virulence and host Immune response in murine hematogenously disseminated candidiasis. *Infection and Immunity*, 78, 4839-4849.
- da Silva, F. F. M., Monte, F. J. Q., De Lemos, T. L. G., Do Nascimento, P. G. G., De Medeiros Costa, A. K. & De Paiva, L. M. M. 2018. Eugenol derivatives: synthesis, characterization, and evaluation of antibacterial and antioxidant activities. *Chemistry Central Journal*, 12.
- Deepa, K., Jeevitha, T. & Michael, A. 2015. *In vitro* evaluation of virulence factors of *Candida* species isolated from oral cavity. *Journal of Microbiology and Antimicrobials*, 7, 28-32.
- de Oliveira Pereira, F., Mendes, J. M. & de Oliveira Lima, E. 2013. Investigation on mechanism of antifungal activity of eugenol against *Trichophyton rubrum*. *Medical Mycology*, 51, 507-513.
- De Paula, S. B., Bartelli, T. F., Di Raimo, V., Santos, J. P., Morey, A. T., Bosini, M. A., Nakamura, C. V., Yamauchi, L. M. & Yamada-Ogatta, S. F. 2014. Effect of eugenol on cell surface hydrophobicity, adhesion, and biofilm of *Candida tropicalis* and *Candida*

- dubliniensis* isolated from oral cavity of HIV-infected patients. *Evidence-Based Complementary and Alternative Medicine*, 2014, 1-8.
- Denning, D. W. 2003. Echinocandin antifungal drugs. *The Lancet*, 362, 1142-1151.
- Dhingra, S. & Cramer, R. A. 2017. Regulation of sterol biosynthesis in the human fungal pathogen *Aspergillus fumigatus*: Opportunities for therapeutic development. *Frontiers in Microbiology*, 8.
- Dias, D. A., Urban, S. & Roessner, U. 2012. A historical overview of natural products in drug discovery. *Metabolites*, 2, 303-336.
- Diasio, R. B., Bennett, J. E. & Myers, C. E. 1978. Mode of action of 5-fluorocytosine. *Biochemical Pharmacology*, 27, 703-707.
- Donlan, R. 2001. Biofilms and device-associated infections. *Emerging Infectious Diseases*, 7, 277-281.
- Douglas, L. M. & Konopka, J. B. 2014. Fungal membrane organization: The eisosome concept. *Annual Review of Microbiology*, 68, 377-393.
- Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J. & Rogers, P. D. 2008. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical *Candida albicans* isolate. *Eukaryotic Cell*, 7, 1180-1190.
- Edlind, T. D. & Katiyar, S. K. 2010. Mutational analysis of flucytosine resistance in *Candida glabrata*. *Antimicrobial Agents and Chemotherapy*, 54, 4733-4738.
- Ekor, M. 2014. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in Pharmacology*, 4:177.
- Espinel-Ingroff, A. 2008. Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos. *Revista Iberoamericana de Micología*, 25, 101-106.
- Fidel, P. L. 2011. *Candida*-host interactions in HIV disease. *Advances in Dental Research*, 23, 45-49.

- Garcia-Cuesta, C., Sarrion-Perez, M. G. & Bagan, J. V. 2014. Current treatment of oral candidiasis: A literature review. *Journal of Clinical and Experimental Dentistry*, e576-e582.
- Ghannoum, M. A. 2000. Potential role of phospholipases in virulence and fungal pathogenesis. *Clinical Microbiology Reviews*, 13, 122-143.
- Ghannoum, M. A. & Rice, L. B. 1999. Antifungal Agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. *Clinical Microbiology Reviews*, 12, 501-517.
- Gourlay, C. W., Du, W. & Ayscough, K. R. 2006. Apoptosis in yeast? mechanisms and benefits to a unicellular organism. *Molecular Microbiology*, 62, 1515-1521.
- Govender, N. P., Magobo, R. E., Mpembe, R., Mhlanga, M., Matlapeng, P., Corcoran, C., Govind, C., Lowman, W., Senekal, M. & Thomas, J. 2018. *Candida auris* in South Africa, 2012–2016. *Emerging Infectious Diseases*, 24, 2036-2040.
- Govender, N. P., Patel, J., Magobo, R. E., Naicker, S., Wadula, J., Whitelaw, A., Coovadia, Y., Kularatne, R., Govind, C., Lockhart, S. R. & Zietsman, I. L. 2016. Emergence of azole-resistant *Candida parapsilosis* causing bloodstream infection: results from laboratory-based sentinel surveillance in South Africa. *Journal of Antimicrobial Chemotherapy*, 71, 1994-2004.
- Gow, N. a. R., Brown, A. J. P. & Odds, F. C. 2002. Fungal morphogenesis and host invasion. *Current Opinion in Microbiology*, 5, 366-371.
- Gow, N. a. R. & Hube, B. 2012. Importance of the *Candida albicans* cell wall during commensalism and infection. *Current Opinion in Microbiology*, 15, 406-412.
- Grubb, S. E. W., Murdoch, C., Sudbery, P. E., Saville, S. P., Lopez-Ribot, J. L. & Thornhill, M. H. 2008. *Candida albicans*-endothelial cell interactions: a key step in the pathogenesis of systemic candidiasis. *Infection and Immunity*, 76, 4370-4377.

- Guaragnella, N., Ždralević, M., Antonacci, L., Passarella, S., Marra, E. & Giannattasio, S. 2012. The role of mitochondria in yeast programmed cell death. *Frontiers in Oncology*, 2.
- Gurnani, N., Mehta, D., Gupta, M. & Mehta, B. K. 2014. Natural products: Source of potential drugs. *African Journal of Basic & Applied Sciences*, 6, 171-186.
- Halbandge, S. D., Mortale, S. P., Jadhav, A. K., Kharat, K. & Karuppayil, S. M. 2017. Differential sensitivities of various growth modes of *Candida albicans* to sixteen molecules of plant origin. *Journal of Pharmacognosy and Phytochemistry*, 6, 306-318.
- Hamill, R. J. 2013. Amphotericin B formulations: A comparative review of efficacy and toxicity. *Drugs*, 73, 919-934.
- Haque, F., Alfatah, M., Ganesan, K. & Bhattacharyya, M. S. 2016. Inhibitory effect of Sophorolipid on *Candida albicans* biofilm formation and hyphal growth. *Scientific Reports*, 6.
- Hata, M., Ishii, Y., Watanabe, E., Uoto, K., Kobayashi, S., Yoshida, K.-I., Otani, T. & Ando, A. 2010. Inhibition of ergosterol synthesis by novel antifungal compounds targeting C-14 reductase. *Medical Mycology*, 48, 613-621.
- Hawksworth, D. L. 2001. The magnitude of fungal diversity: the 1.5 million species estimate revisited. *Mycological Research*, 105, 1422-1432.
- He, M., Du, M., Fan, M. & Bian, Z. 2007. In vitro activity of eugenol against *Candida albicans* biofilms. *Mycopathologia*, 163, 137-143.
- Hernández-Chávez, M., Pérez-García, L., Niño-Vega, G. & Mora-Montes, H. 2017. Fungal strategies to evade the host immune recognition. *Journal of Fungi*, 3, 51.
- Hipólito, T. M. M., Bastos, G. T. L., Barbosa, T. W. L., Souza, T. B., Coelho, L. F. L., Dias, A. L. T., Rodríguez, I. C., Dos Santos, M. H., Dias, D. F., Franco, L. L. & Carvalho, D. T. 2018. Synthesis, activity, and docking studies of eugenol-based glucosides as new agents against *Candida* sp. *Chemical Biology & Drug Design*, 92, 1514-1524.

- Hube, B., Rüchel, R., Monod, M., Sanglard, D. & Odds, F. C. 1998. Functional aspects of secreted *Candida* proteinases. *Aspartic Proteinases*. Springer US.
- Hube, B., Stehr, F., Bossenz, M., Mazur, A., Kretschmar, M. & Schäfer, W. 2000. Secreted lipases of *Candida albicans*: cloning, characterisation and expression analysis of a new gene family with at least ten members. *Archives of Microbiology*, 174, 362-374.
- Huh, G.-H., Damsz, B., Matsumoto, T. K., Reddy, M. P., Rus, A. M., Ibeas, J. I., Narasimhan, M. L., Bressan, R. A. & Hasegawa, P. M. 2002. Salt causes ion disequilibrium-induced programmed cell death in yeast and plants. *The Plant Journal*, 29, 649-659.
- Ignéy, F. H. & Krammer, P. H. 2002. Death and anti-death: tumour resistance to apoptosis. *Nature Reviews Cancer*, 2, 277-288.
- Ilkit, M. & Guzel, A. B. 2011. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. *Critical Reviews in Microbiology*, 37, 250-261.
- Jabra-Rizk, M. A., Kong, E. F., Tsui, C., Nguyen, M. H., Clancy, C. J., Fidel, P. L. & Noverr, M. 2016. *Candida albicans* pathogenesis: Fitting within the host-microbe damage response framework. *Infection and Immunity*, 84, 2724-2739.
- Jacobsen, I. D., Wilson, D., Wächtler, B., Brunke, S., Naglik, J. R. & Hube, B. 2012. *Candida albicans* dimorphism as a therapeutic target. *Expert Review of Anti-infective Therapy*, 10, 85-93.
- Jia, C., Zhang, J., Yu, L., Wang, C., Yang, Y., Rong, X., Xu, K. & Chu, M. 2019. Antifungal activity of Coumarin against *Candida albicans* is related to apoptosis. *Frontiers in Cellular and Infection Microbiology*, 8.
- Jones, T., Federspiel, N. A., Chibana, H., Dungan, J., Kalman, S., Magee, B. B., Newport, G., Thorstenson, Y. R., Agabian, N., Magee, P. T., Davis, R. W. & Scherer, S. 2004. The diploid genome sequence of *Candida albicans*. *Proceedings of the National Academy of Sciences*, 101, 7329-7334.

- Kabir, M. A., Hussain, M. A. & Ahmad, Z. 2012. *Candida albicans*: A model organism for studying fungal pathogens. *ISRN Microbiology*, 2012, 1-15.
- Kanafani, Z. A. & Perfect, J. R. 2008. Resistance to antifungal agents: mechanisms and clinical impact. *Clinical Infectious Diseases*, 46, 120-128.
- Karkowska-Kuleta, J., Rapala-Kozik, M. & Kozik, A. 2009. Fungi pathogenic to humans: molecular bases of virulence of *Candida albicans*, *Cryptococcus neoformans* and *Aspergillus fumigatus*. *Acta Biochimica Polonica*, 56.
- Kaufman, D. A., Coggins, S. A., Zanelli, S. A. & Weitkamp, J.-H. 2017. Congenital cutaneous candidiasis: Prompt systemic treatment is associated with improved outcomes in neonates. *Clinical Infectious Diseases*, 64, 1387-1395.
- Kett, D. H., Azoulay, E., Echeverria, P. M. & Vincent, J.-L. 2011. *Candida* bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. *Critical Care Medicine*, 39, 665-670.
- Khameneh, B., Iranshahy, M., Soheili, V. & Fazly Bazzaz, B. S. 2019. Review on plant antimicrobials: a mechanistic viewpoint. *Antimicrobial Resistance & Infection Control*, 8.
- Khan, A., Ahmad, A., Khan, L. A. & Manzoor, N. 2014. *Ocimum sanctum* (L.) essential oil and its lead molecules induce apoptosis in *Candida albicans*. *Research in Microbiology*, 165, 411-419.
- Khan, M. S., Ahmad, I. & Cameotra, S. 2013. Phenyl aldehyde and propanoids exert multiple sites of action towards cell membrane and cell wall targeting ergosterol in *Candida albicans*. *AMB Express*, 3, 54.
- Khan, M. S. A., Ahmad, I., Aqil, F., Owais, M., Shahid, M. & Musarrat, J. 2010. Virulence and pathogenicity of fungal pathogens with special reference to *Candida albicans*. *Combating Fungal Infections*. Springer Berlin Heidelberg. pp: 21-45.

- Khan, M. S. A., Malik, A. & Ahmad, I. 2012. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of *Candida albicans*. *Medical Mycology*, 50, 33-42.
- King, D. A., Hannum, D. M., Qi, J.-S. & Hurst, J. K. 2004. HOCl-mediated cell death and metabolic dysfunction in the yeast *Saccharomyces cerevisiae*. *Archives of Biochemistry and Biophysics*, 423, 170-181.
- Kontoyiannis, D. P. & Lewis, R. E. 2002. Antifungal drug resistance of pathogenic fungi. *The Lancet*, 359, 1135-1144.
- Kreusch, A. & Karstaedt, A. S. 2013. Candidemia among adults in Soweto, South Africa, 1990–2007. *International Journal of Infectious Diseases*, 17, e621-e623.
- Kullberg, B. J. & Arendrup, M. C. 2015. Invasive candidiasis. *New England Journal of Medicine*, 373, 1445-1456.
- Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R. & Dhull, D. K. 2015. Current knowledge and pharmacological profile of berberine: An update. *European Journal of Pharmacology*, 761, 288-297.
- Nigam, P. K. 2015. Antifungal drugs and resistance: Current concepts. *Our Dermatology Online*, 6, 212-221.
- Kutlubay, Z., Yardımcı, G., Kantarcıoğlu, A. S. & Serdaroğlu, S. 2017. Acral manifestations of fungal infections. *Clinics in Dermatology*, 35, 28-39.
- Langenbeck, B. 1839. Auffingung von Pilzen aus der Schleimhaut der Speiseröhre einer Typhus-Leiche. *Neue Not Geb Natur-uHelik. Froriep*, 12, 145-147.
- Latifah-Munirah, B., Himratul-Aznita, W. H. & Mohd Zain, N. 2015. Eugenol, an essential oil of clove, causes disruption to the cell wall of *Candida albicans* (ATCC 14053). *Frontiers in Life Science*, 8, 231-240.
- Leidich, S. D., Ibrahim, A. S., Fu, Y., Koul, A., Jessup, C., Vitullo, J., Fonzi, W., Mirbod, F., Nakashima, S., Nozawa, Y. & Ghannoum, M. A. 1998. Cloning and disruption of

- caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *Journal of Biological Chemistry*, 273, 26078-26086.
- Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B. & Lortholary, O. 2009. Epidemiology, management, and risk factors for death of invasive *Candida* infections in critical care: A multicenter, prospective, observational study in France (2005–2006). *Critical Care Medicine*, 37, 1612-1618.
- Lim, C. S. Y., Rosli, R., Seow, H. F. & Chong, P. P. 2012. *Candida* and invasive candidiasis: back to basics. *European Journal of Clinical Microbiology & Infectious Diseases*, 31, 21-31.
- Liu, Y. & Filler, S. G. 2011. *Candida albicans* Als3, a Multifunctional adhesin and invasin. *Eukaryotic Cell*, 10, 168-173.
- Lone, S. A. & Ahmad, A. 2019. *Candida auris* —the growing menace to global health. *Mycoses*, 62, 620-637.
- Ludovico, P., Rodrigues, F., Almeida, A., Silva, M. T., Barrientos, A. & Côrte-Real, M. 2002. Cytochrome c release and mitochondria involvement in programmed cell death induced by acetic acid in *Saccharomyces cerevisiae*. *Molecular Biology of the Cell*, 13, 2598-2606.
- Lv, Q.-Z., Yan, L. & Jiang, Y.-Y. 2016. The synthesis, regulation, and functions of sterols in *Candida albicans*: Well-known but still lots to learn. *Virulence*, 7, 649-659.
- Madeo, F., Engelhardt, S., Herker, E., Lehmann, N., Maldener, C., Proksch, A., Wissing, S. & Fröhlich, K.-U. 2002. Apoptosis in yeast: a new model system with applications in cell biology and medicine. *Current Genetics*, 41, 208-216.
- Madeo, F., Fröhlich, E. & Fröhlich, K.-U. 1997. A yeast mutant showing diagnostic markers of early and late apoptosis. *The Journal of Cell Biology*, 139, 729-734.

- Madeo, F., Fröhlich, E., Ligr, M., Grey, M., Sigrist, S. J., Wolf, D. H. & Fröhlich, K.-U. 1999. Oxygen stress: A regulator of apoptosis in yeast. *The Journal of Cell Biology*, 145, 757-767.
- Madeo, F., Herker, E., Wissing, S., Jungwirth, H., Eisenberg, T. & Fröhlich, K.-U. 2004. Apoptosis in yeast. *Current Opinion in Microbiology*, 7, 655-660.
- Maertens, J. A. 2004. History of the development of azole derivatives. *Clinical Microbiology and Infection*, 10, 1-10.
- Makhado, N. A., Ismail, F., Dangor, Y., Chephe, T. J. H., Hoosen, A. A. & Nchabeleng, M. 2014. Antifungal susceptibility profile of yeast isolates from sterile sites at a tertiary hospital in South Africa. *Southern African Journal of Infectious Diseases*, 29, 97-100.
- Mancera, E., Frazer, C., Porman, A. M., Ruiz-Castro, S., Johnson, A. D. & Bennett, R. J. 2019. Genetic modification of closely related *Candida* Species. *Frontiers in Microbiology*, 10.
- Mansur, A. T., Aydingoz, I. E. & Artunkal, S. 2012. Facial *Candida* folliculitis: possible role of sexual contact. *Mycoses*, 55, e20-2.
- Marr, K. A., White, T. C., Van Burik, J. a. H. & Bowden, R. A. 1997. Development of fluconazole resistance in *Candida albicans* causing disseminated infection in a patient undergoing marrow transplantation. *Clinical Infectious Diseases*, 25, 908-910.
- Marriott, D. J. E., Playford, E. G., Chen, S., Slavin, M., Nguyen, Q., Ellis, D. & Sorrell, T. C. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. *Critical Care*, 13, R115.
- Mavor, A., Thewes, S. & Hube, B. 2005. Systemic fungal infections caused by *Candida* Species: epidemiology, infection process and virulence attributes. *Current Drug Targets*, 6, 863-874.
- Mayer, L. 1862. Die Pflanzlichen parasiten der weiblichen Sexualorgane in ihrer praktischen Bedeutung. *Msschr Geburtssch Frauenkrank*, 20, 2-16.

- Mayer, F. L., Wilson, D. & Hube, B. 2013. *Candida albicans* pathogenicity mechanisms. *Virulence*, 4, 119-128.
- Mazzoni, C. & Falcone, C. 2008. Caspase-dependent apoptosis in yeast. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1783, 1320-1327.
- Metin, A., Genç Dilek, N. & Gunes Bilgili, S. 2018. Recurrent candidal intertrigo: challenges and solutions. *Clinical, Cosmetic and Investigational Dermatology*, Volume 11, 175-185.
- Mnge, P., Okeleye, B. I., Vasaikar, S. D. & Apalata, T. 2017. Species distribution and antifungal susceptibility patterns of *Candida* isolates from a public tertiary teaching hospital in the Eastern Cape Province, South Africa. *Brazilian Journal of Medical and Biological Research*, 50.
- Modjtahedi, N., Giordanetto, F., Madeo, F. & Kroemer, G. 2006. Apoptosis-inducing factor: vital and lethal. *Trends in Cell Biology*, 16, 264-272.
- Morace, G., Perdoni, F. & Borghi, E. 2014. Antifungal drug resistance in *Candida* species. *Journal of Global Antimicrobial Resistance*, 2, 254-259.
- Morio, F., Jensen, R. H., Le Pape, P. & Arendrup, M. C. 2017. Molecular basis of antifungal drug resistance in yeasts. *International Journal of Antimicrobial Agents*, 50, 599-606.
- Morio, F., Loge, C., Besse, B., Hennequin, C. & Le Pape, P. 2010. Screening for amino acid substitutions in the *Candida albicans* Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. *Diagnostic Microbiology and Infectious Disease*, 66, 373-384.
- Morschhäuser, J. 2002. The genetic basis of fluconazole resistance development in *Candida albicans*. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1587, 240-248.

- Murciano, C., Moyes, D. L., Runglall, M., Tobouti, P., Islam, A., Hoyer, L. L. & Naglik, J. R. 2012. Evaluation of the role of *Candida albicans* agglutinin-like sequence (Als) proteins in human oral epithelial cell interactions. *PLoS ONE*, 7, e33362.
- Naglik, J. R., Challacombe, S. J. & Hube, B. 2003. *Candida albicans* Secreted aspartyl proteinases in virulence and pathogenesis. *Microbiology and Molecular Biology Reviews*, 67, 400-428.
- Naglik, J. R., Moyes, D., Makwana, J., Kanzaria, P., Tsihlaki, E., Weindl, G., Tappuni, A. R., Rodgers, C. A., Woodman, A. J., Challacombe, S. J., Schaller, M. & Hube, B. 2008. Quantitative expression of the *Candida albicans* secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. *Microbiology*, 154, 3266-3280.
- Naglik, J. R., Moyes, D. L., Wächtler, B. & Hube, B. 2011. *Candida albicans* interactions with epithelial cells and mucosal immunity. *Microbes and Infection*, 13, 963-976.
- Naicker, S. D., Govender, N., Patel, J., Zietsman, I. L., Wadula, J., Coovadia, Y., Kularatne, R., Seetharam, S. & Govender, N. P. 2016. Comparison of species-level identification and antifungal susceptibility results from diagnostic and reference laboratories for bloodstream *Candida* surveillance isolates, South Africa, 2009–2010. *Medical Mycology*, 54, 816-824.
- Newman, D. J. & Cragg, G. M. 2016. Natural products as sources of new drugs from 1981 to 2014. *Journal of Natural Products*, 79, 629-661.
- Ngo, H. X., Garneau-Tsodikova, S. & Green, K. D. 2016. A complex game of hide and seek: the search for new antifungals. *Medicinal Chemistry Communications*, 7, 1285-1306.
- Nobile, Clarissa j., Fox, Emily p., Nett, Jeniel e., Sorrells, Trevor r., Mitrovich, Quinn m., Hernday, Aaron d., Tuch, Brian b., Andes, David r. & Johnson, Alexander d. 2012. A recently evolved transcriptional network controls biofilm development in *Candida albicans*. *Cell*, 148, 126-138.

- Nobile, C. J. & Johnson, A. D. 2015. *Candida albicans* biofilms and human disease. *Annual Review of Microbiology*, 69, 71-92.
- Nobile, C. J., Schneider, H. A., Nett, J. E., Sheppard, D. C., Filler, S. G., Andes, D. R. & Mitchell, A. P. 2008. Complementary adhesin function in *C. albicans* biofilm formation. *Current Biology*, 18, 1017-1024.
- Noble, S. M., Gianetti, B. A. & Witchley, J. N. 2017. *Candida albicans* cell-type switching and functional plasticity in the mammalian host. *Nature Reviews Microbiology*, 15, 96-108.
- Odds, F. C. 2009. In *Candida albicans*, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1. *FEMS Yeast Research*, 9, 1091-1101.
- Olea, A., Bravo, A., Martínez, R., Thomas, M., Sedan, C., Espinoza, L., Zambrano, E., Carvajal, D., Silva-Moreno, E. & Carrasco, H. 2019. Antifungal activity of eugenol derivatives against *Botrytis Cinerea*. *Molecules*, 24, 1239.
- Osborne, C. S., Leitner, I., Hofbauer, B., Fielding, C. A., Favre, B. & Ryder, N. S. 2006. Biological, biochemical, and molecular characterization of a new clinical *Trichophyton rubrum* isolate resistant to terbinafine. *Antimicrobial Agents and Chemotherapy*, 50, 2234-2236.
- Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C. & Rex, J. H. 2010. An insight into the antifungal pipeline: Selected new molecules and beyond. *Nature Reviews Drug Discovery*, 9, 719-727.
- Patricia, B. G., Ana, I. M., Manuel, D. N. J. J., Amparo, L. L., Maria, M. R. J., Angeles, G. N. M. & Jose, L. R. M. 2016. Esophageal candidiasis in an immunocompetent girl with chronic anaemia. *Journal of Gastroenterology and Digestive Diseases*, 1, 1-24.

- Pawar, P. R., Pawar, V. A. & Aute, R. A. 2014. Role of extracellular hydrolytic enzymes in *Candida albicans* virulence. *International journal of pharmaceutical sciences review and research*, 2, pp:1521-1532.
- Perfect, J. R. 2017. The antifungal pipeline: a reality check. *Nature Reviews Drug Discovery*, 16, 603-616.
- Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. *Drug Resistance Updates*, 10, 121-130.
- Perlin, D. S. 2011. Current perspectives on echinocandin class drugs. *Future Microbiology*, 6, 441-457.
- Perlin, D. S., Rautemaa-Richardson, R. & Alastruey-Izquierdo, A. 2017. The global problem of antifungal resistance: prevalence, mechanisms, and management. *The Lancet Infectious Diseases*, 17, e383-e392.
- Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P. & Horn, D. 2012. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. *Diagnostic Microbiology and Infectious Disease*, 74, 323-331.
- Pfaller, M. A. & Diekema, D. J. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. *Clinical Microbiology Reviews*, 20, 133-163.
- Pfaller, M. A., Messer, S. A., Woosley, L. N., Jones, R. N. & Castanheira, M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. *Journal of Clinical Microbiology*, 51, 2571-2581.

- Phan, Q. T., Myers, C. L., Fu, Y., Sheppard, D. C., Yeaman, M. R., Welch, W. H., Ibrahim, A. S., Edwards, J. E. & Filler, S. G. 2007. Als3 is a *Candida albicans* invasin that binds to cadherins and induces endocytosis by host cells. *PLOS Biology*, 5, e64.
- Phillips, A. J., Sudbery, I. & Ramsdale, M. 2003. Apoptosis induced by environmental stresses and amphotericin B in *Candida albicans*. *Proceedings of the National Academy of Sciences*, 100, 14327-14332.
- Piccione, D., Mirabelli, S., Minto, N. & Bouklas, T. 2019. Difficult but not impossible: in search of an anti-*Candida* vaccine. *Current Tropical Medicine Reports*, 6, 42-49.
- Pierce, C. G. & Lopez-Ribot, J. L. 2013. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. *Expert Opinion on Drug Discovery*, 8, 1117-1126.
- Pinto, E., Vale-Silva, L., Cavaleiro, C. & Salgueiro, L. 2009. Antifungal activity of the clove essential oil from *Syzygium aromaticum* on *Candida*, *Aspergillus* and dermatophyte species. *Journal of Medical Microbiology*, 58, 1454-1462.
- Polak, A. & Scholer, H. J. 1975. Mode of action of 5-fluorocytosine and mechanisms of resistance. *Chemotherapy*, 21, 113-130.
- Prasad, R., De Wergifosse, P., Goffeau, A. & Balzi, E. 1995. Molecular cloning and characterization of a novel gene of *Candida albicans*, CDR1, conferring multiple resistance to drugs and antifungals. *Current Genetics*, 27, 320-329.
- Prasad, R. & Kapoor, K. 2004. Multidrug resistance in yeast *Candida*. *International Review of Cytology*, 242, 215-248.
- Price, M. F., Wilkinson, I. D. & Gentry, L. O. 1982. Plate method for detection of phospholipase activity in *Candida albicans*. *Medical Mycology*, 20, 7-14.
- Ramage, G., Wickers, B. L. & Lopez-Ribot, J. L. 2001. Biofilms of *Candida albicans* and their associated resistance to antifungal agents. *American Clinical Laboratory*, 20, 42-44.

- Raut, J. S., Shinde, R. B., Chauhan, N. M. & Mohan Karuppayil, S. 2013. Terpenoids of plant origin inhibit morphogenesis, adhesion, and biofilm formation by *Candida albicans*. *Biofouling*, 29, 87-96.
- Rhodus, N. L. 2012. Treatment of oral candidiasis. *Northwest Dentistry*, 91, 32–33.
- Rigopoulos, D., Gregoriou, S., Belyayeva, Y., Larios, G., Gkouvi, A. & Katsambas, A. 2009. Acute paronychia caused by lapatinib therapy. *Clinical and Experimental Dermatology*, 34, 94-95.
- Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D. & Cowen, L. E. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. *PLoS Pathogens*, 7, e1002257.
- Robin, C. 1853. Natural history of parasitic plants which grow on man and on living animals, J.-B. Ballière.
- Roemer, T. & Krysan, D. J. 2014. Antifungal drug development: challenges, unmet clinical needs, and new approaches. *Cold Spring Harbor perspectives in medicine*, 4, a019703.
- Römling, U. & Balsalobre, C. 2012. Biofilm infections, their resilience to therapy and innovative treatment strategies. *Journal of Internal Medicine*, 272, 541-561.
- Sachin, C. D., Ruchi, K. & Santosh, S. 2012. *In vitro* evaluation of proteinase, phospholipase and haemolysin activities of *Candida* species isolated from clinical specimens. *International Journal of Medicine and Biomedical Research*, 1, 153-157.
- Salerno, C., Pascale, M., Contaldo, M., Esposito, V., Busciolano, M., Milillo, L., Guida, A., Petruzzi, M. & Serpico, R. 2011. *Candida*-associated denture stomatitis. *Medicina Oral Patología Oral y Cirugía Bucal*, e139-e143.
- Sanglard, D., Ischer, F., Parkinson, T., Falconer, D. & Bille, J. 2003. *Candida albicans* mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. *Antimicrobial Agents and Chemotherapy*, 47, 2404-2412.

- Sardi, J. C. O., Mendes Giannini, M. J. S., Bernardi, T., Scorzoni, L. & Fusco-Almeida, A. M. 2013. *Candida* species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. *Journal of Medical Microbiology*, 62, 10-24.
- Saville, S. P., Lazzell, A. L., Monteagudo, C. & Lopez-Ribot, J. L. 2003. Engineered control of cell morphology *in vivo* reveals distinct roles for yeast and filamentous forms of *Candida albicans* during infection. *Eukaryotic Cell*, 2, 1053-1060.
- Schaller, M., Borelli, C., Korting, H. C. & Hube, B. 2005. Hydrolytic enzymes as virulence factors of *Candida albicans*. *Mycoses*, 48, 365-377.
- Selmecki, A. 2006. Aneuploidy and isochromosome formation in drug-resistant *Candida albicans*. *Science*, 313, 367-370.
- Shapiro, R. S., Robbins, N. & Cowen, L. E. 2011. Regulatory circuitry governing fungal development, drug resistance, and disease. *Microbiology and Molecular Biology Reviews*, 75, 213-267.
- Shareck, J. & Belhumeur, P. 2011. Modulation of morphogenesis in *Candida albicans* by various small molecules. *Eukaryotic Cell*, 10, 1004-1012.
- Shreaz, S., Bhatia, R., Khan, N., Muralidhar, S., F. Basir, S., Manzoor, N. & Ahmad Khan, L. 2011. Exposure of *Candida* to p-anisaldehyde inhibits its growth and ergosterol biosynthesis. *The Journal of General and Applied Microbiology*, 57, 129-136.
- Shu, Y.-Z. 1998. Recent natural products based drug development: A pharmaceutical industry perspective. *Journal of Natural Products*, 61, 1053-1071.
- Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B. & Fridkin, S. 2013. Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009–2010. *Infection Control & Hospital Epidemiology*, 34, 1-14.

- Silva, R. D., Sotoca, R., Johansson, B., Ludovico, P., Sansonetty, F., Silva, M. T., Peinado, J. M. & Côrte-Real, M. 2005. Hyperosmotic stress induces metacaspase- and mitochondria-dependent apoptosis in *Saccharomyces cerevisiae*. *Molecular Microbiology*, 58, 824-834.
- Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W. & Azeredo, J. 2011. Adherence and biofilm formation of non-*Candida albicans* *Candida* species. *Trends in Microbiology*, 19, 241-247.
- Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W. & Azeredo, J. 2012. *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*: biology, epidemiology, pathogenicity and antifungal resistance. *FEMS Microbiology Reviews*, 36, 288-305.
- Silver, P. M., Oliver, B. G. & White, T. C. 2004. Role of *Candida albicans* transcription factor Upc2p in drug resistance and sterol metabolism. *Eukaryotic Cell*, 3, 1391-1397.
- Simon, H. U., Haj-Yehia, A. & Levi-Schaffer, F. 2000. Role of reactive oxygen species (ROS) in apoptosis induction. *Apoptosis*, 5, 415-418.
- Sokol-Anderson, M. L., Brajtburg, J. & Medoff, G. 1986. Amphotericin B-induced oxidative damage and killing of *Candida albicans*. *Journal of Infectious Diseases*, 154, 76-83.
- Spampinato, C. & Leonardi, D. 2013. *Candida* Infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. *BioMed Research International*, 2013, 1-13.
- Staib, P. & Morschhäuser, J. 2007. Chlamydospore formation in *Candida albicans* and *Candida dubliniensis*? an enigmatic developmental programme. *Mycoses*, 50, 1-12.
- Staniszewska, M., Bondaryk, M., Siennicka, K., Pilat, J., Schaller, M. & Kurzatkowski, W. 2012. Role of aspartic proteinases in *Candida albicans* virulence. Part I. Substrate specificity of aspartic proteinases and *Candida albicans* pathogenesis. *Postępy mikrobiologii*, 51(2) p:72.

- Stehr, F., Felk, A., Gacser, A., Kretschmar, M., Mahns, B., Neuber, K., Hube, B. & Schafer, W. 2004. Expression analysis of the lipase gene family during experimental infections and in-patient samples. *FEMS Yeast Research*, 4, 401-408.
- Stehr, F., Kretschmar, M., Kröger, C., Hube, B. & Schäfer, W. 2003. Microbial lipases as virulence factors. *Journal of Molecular Catalysis B: Enzymatic*, 22, 347-355.
- St-Germain, G., Laverdière, M., Pelletier, R., René, P., Bourgault, A.-M., Lemieux, C. & Libman, M. 2008. Epidemiology and antifungal susceptibility of blood stream *Candida* isolates in quebec: Report on 453 cases between 2003 and 2005. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 19, 55-62.
- Stratton, C. F., Newman, D. J. & Tan, D. S. 2015. Cheminformatic comparison of approved drugs from natural product versus synthetic origins. *Bioorganic & Medicinal Chemistry Letters*, 25, 4802-4807.
- Wilkinson, J. S. 1849. Some remarks upon the development of epiphytes. *The Lancet*, 54, 448-451.
- Sudbery, P., Gow, N. & Berman, J. 2004. The distinct morphogenic states of *Candida albicans*. *Trends in Microbiology*, 12, 317-324.
- Sundstrom, P. 2002. Reevaluation of the role of HWP1 in systemic candidiasis by use of *Candida albicans* strains with selectable marker URA3 targeted to the ENO1 locus. *Infection and Immunity*, 70, 3281-3283.
- Sundstrom, P., Balish, E. & Allen, Carl m. 2002. Essential role of the *Candida albicans* transglutaminase substrate, hyphal wall protein 1, in lethal or oesophageal candidiasis in immunodeficient mice. *The Journal of Infectious Diseases*, 185, 521-530.
- Taylor, B. N., Hannemann, H., Sehnal, M., Biesemeier, A., Schweizer, A., Rollinghoff, M. & Schroppel, K. 2005. Induction of SAP7 correlates with virulence in an intravenous infection model of candidiasis but not in a vaginal infection model in mice. *Infection and Immunity*, 73, 7061-7063.

- Terézhalmy, G. T. & Huber, M. A. 2011. Oropharyngeal candidiasis: etiology, epidemiology, clinical manifestations, diagnosis, and treatment. *dentalcare.com*. pp: 1-16.
- Theiss, S., Ishdorj, G., Brenot, A., Kretschmar, M., Lan, C.-Y., Nichterlein, T., Hacker, J., Nigam, S., Agabian, N. & Köhler, G. A. 2006. Inactivation of the phospholipase B gene PLB5 in wild-type *Candida albicans* reduces cell-associated phospholipase A2 activity and attenuates virulence. *International Journal of Medical Microbiology*, 296, 405-420.
- Thompson, D. S., Carlisle, P. L. & Kadosh, D. 2011. Coevolution of morphology and virulence in *Candida* Species. *Eukaryotic Cell*, 10, 1173-1182.
- Tronchin, G., Pihet, M., Lopes-Bezerra, L. M. & Bouchara, J.-P. 2008. Adherence mechanisms in human pathogenic fungi. *Medical Mycology*, 46, 749-772.
- Tsai, P.-W., Chen, Y.-T., Hsu, P.-C. & Lan, C.-Y. 2013. Study of *Candida albicans* and its interactions with the host: A mini review. *BioMedicine*, 3, 51-64.
- Turner, S. A. & Butler, G. 2014. The *Candida* pathogenic species complex. *Cold Spring Harbor Perspectives in Medicine*, 4, a019778-a019778.
- Tyc, K. M., Kühn, C., Wilson, D. & Klipp, E. 2014. Assessing the advantage of morphological changes in *Candida albicans*: a game theoretical study. *Frontiers in Microbiology*, 5.
- Vandeputte, P., Ferrari, S. & Coste, A. T. 2012. Antifungal resistance and new strategies to control fungal infections. *International Journal of Microbiology*, 2012, 1-26.
- Vazquez, J. A. & Sobel, J. D. 2011. Candidiasis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, eds. *Essentials of Clinical Mycology*, New York: Springer; p:167-206.
- Vediappan, G., Dumontet, V., Pelissier, F. & D'enfert, C. 2013. Gymnemic acids inhibit hyphal growth and virulence in *Candida albicans*. *PLOS One*, 8, e74189.
- Vermes, A. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. *Journal of Antimicrobial Chemotherapy*, 46, 171-179.

- Vila, T., Romo, J. A., Pierce, C. G., Mchardy, S. F., Saville, S. P. & Lopez-Ribot, J. L. 2017. Targeting *Candida albicans* filamentation for antifungal drug development. *Virulence*, 8, 150-158.
- Wadskog, I., Maldener, C., Proksch, A., Madeo, F. & Adler, L. 2004. Yeast lacking the SRO7/SOP1-encoded tumor suppressor homologue show increased susceptibility to apoptosis-like cell death on exposure to NaCl stress. *Molecular Biology of the Cell*, 15, 1436-1444.
- Wang, H., Kong, F., Sorrell, T. C., Wang, B., McNicholas, P., Pantarat, N., Ellis, D., Xiao, M., Widmer, F. & Chen, S. C. A. 2009. Rapid detection of ERG11 gene mutations in clinical *Candida albicans* isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. *BMC Microbiology*, 9, 167.
- Wang, J. M., Bennett, R. J. & Anderson, M. Z. 2018. The genome of the human pathogen *Candida albicans* is shaped by mutation and cryptic sexual recombination. *mBio*, 9.
- Watanabe, N.-A., Miyazaki, M., Horii, T., Sagane, K., Tsukahara, K. & Hata, K. 2012. E1210, a new broad-spectrum antifungal, suppresses *Candida albicans* hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. *Antimicrobial Agents and Chemotherapy*, 56, 960-971.
- Wenzel, R. P. & Gennings, C. 2005. Bloodstream infections due to *Candida* species in the intensive care unit: Identifying especially high-risk patients to determine prevention strategies. *Clinical Infectious Diseases*, 41, S389-S393.
- Williams, D. & Lewis, M. 2011. Pathogenesis and treatment of oral candidosis. *Journal of Oral Microbiology*, 3, 5771.
- Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K. & Beney, J. 2002. The direct cost and incidence of systemic fungal infections. *Value in Health*, 5, 26-34.
- Winner, H. I. & R, Hurley. 1954. *Candida albicans*. Boston, Mass., Little, Brown and Company.

- Wu, X.-Z., Chang, W.-Q., Cheng, A.-X., Sun, L.-M. & Lou, H.-X. 2010. Plagiochin E, an antifungal active macrocyclic bis(bibenzyl), induced apoptosis in *Candida albicans* through a metacaspase-dependent apoptotic pathway. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1800, 439-447.
- Yang, H., Ren, Q. & Zhang, Z. 2008. Cleavage of Mcd1 by caspase-like protease Esp1 promotes apoptosis in budding yeast. *Molecular Biology of the Cell*, 19, 2127-2134.
- Yapar, N. 2014. Epidemiology and risk factors for invasive candidiasis. *Therapeutics and Clinical Risk Management*, 95.
- Zeng, X., Zhang, Y., Zhang, T., Xue, Y., Xu, H. & An, R. 2018. Risk factors of vulvovaginal candidiasis among women of reproductive age in Xi'an: A cross-sectional study. *BioMed Research International*, 2018, 1-8.
- Zeng, Y.-B., Qian, Y.-S., Ma, L. & Gu, H.-N. 2007. Genome-wide expression profiling of the response to terbinafine in *Candida albicans* using a cDNA microarray analysis. *Chinese Medical Journal*, 120, 807-813.
- Zhang, P., Zhang, E., Xiao, M., Chen, C. & Xu, W. 2013. Study of anti-inflammatory activities of α -d-glucosylated eugenol. *Archives of Pharmacal Research*, 36, 109-115.
- Zhu, W. & Filler, S. G. 2010. Interactions of *Candida albicans* with epithelial cells. *Cellular Microbiology*, 12, 273-282.
- Zordan, R. & Cormack, B. 2012. Adhesins on opportunistic fungal pathogens. In: Calderone RA, Clancy CJ, ed. *Candida and Candidiasis: American Society of Microbiology Press*, Washington, DC, pp: 243-259.
- Zischka, H., Braun, R. J., Marantidis, E. P., Büringer, D., Bornhövd, C., Hauck, S. M., Demmer, O., Gloeckner, C. J., Reichert, A. S., Madeo, F. & Ueffing, M. 2006. Differential Analysis of *Saccharomyces cerevisiae* mitochondria by free flow electrophoresis. *Molecular & Cellular Proteomics*, 5, 2185-2200.

Zotchev, S. 2003. Polyene macrolide antibiotics and their applications in human therapy.
Current Medicinal Chemistry, 10, 211-223.